All In Biotech

Free tool

FAERS Monitor: Tryvio

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217686 or its brand name (Tryvio, Aprocitentan). Reports on generic versions are filed under their own applications.

Reports

22

Serious

13

59% of reports

Hospitalization

5

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea3
  • malaise3
  • heart rate increased2
  • oedema peripheral2
  • peripheral swelling2
  • weight increased2
  • abdominal discomfort1
  • anaemia1
  • aortic valve replacement1
  • arthralgia1
  • asthenia1
  • atrial fibrillation1
  • blood sodium decreased1
  • blood urine1
  • breast cancer1

Reports by year received

View as table
YearReports
20211
202511
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,137 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood urine1992.7146.1247
aortic valve replacement1763.8112.5190
blood sodium decreased150.77.512
heart rate increased219.35.119
oedema peripheral215.74.215
peripheral swelling212.43.311
breast cancer110.31.52
atrial fibrillation19.81.42
weight increased28.52.37
malaiseSignal36.52.39
abdominal discomfort15.70.81
dyspnoeaSignal35.11.86
anaemia15.00.70
asthenia12.50.40
arthralgia12.30.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.